Assessment, measures and approaches to easing caregiver burden in Alzheimer's disease.
The reduction of caregiver burden for those caring for patients with Alzheimer's disease (AD) is especially important given the prevalence of AD as populations age. This paper reviews the complex nature of caregiver burden, how it is measured, and possible interventions that may affect caregiver burden. Caregiver characteristics as well as symptoms exhibited by patients contribute to burden. A number of specific quantitative measures which have been developed to better evaluate caregiver burden are discussed. Such measures are also useful in measuring the impact of interventions on caregiver burden. Pharmacological treatment of patients with AD through the use of acetylcholinesterase inhibitors has positively affected cognition, activities of daily living, and behavioural problems. These benefits significantly reduce caregiver burden. The same is true for psychosocial interventions for the caregiver. It has been suggested that combining both approaches should be utilised for optimal management. Our knowledge of caregiver burden has greatly increased over the past two decades with clear benefits for both patients and caregivers. However, many aspects still clearly require further research. Given the significance of caregiver burden, various aspects have been extensively studied including contributing and protective factors, quantitative assessment, and pharmacological and psychosocial intervention. It is important for clinicians to be aware of this knowledge so that they can effectively incorporate it into their treatment plans for those affected by AD.
Farcnik
Karl
K
Neuropharmacology Clinic, Toronto Western Hospital, Ontario, Canada.
Persyko
Michelle S
MS
D000544:Alzheimer Disease / Q000188:drug therapy / Q000451:nursing* / Q000523:psychology; D017028:Caregivers / Q000523:psychology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D017281:Cost of Illness; D003858:Dependency, Psychological; D006801:Humans
D002800:Cholinesterase Inhibitors